Business Context and Reporting Period
Company: GAXOS.AI INC. (formerly The NFT Gaming Company, Inc.)
Reporting Period: Quarter ended September 30, 2024 (Q3 2024)
Business Overview: A technology company developing AI-driven applications for gaming ("Gaxos Gaming") and health optimization ("Gaxos Health"). The company recently launched AI-powered health optimization products and is developing a generative AI solution for game developers expected in Q4 2024. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|
| Revenue | $2,704 | $2,723 | $0 |
| Net Loss | $(864,410) | $(2,585,793) | $(3,147,134) |
| Loss Per Share (Basic/Diluted) | $(0.61) | $(1.95) | $(3.20) |
| Operating Expenses | $908,573 | $2,806,934 | $3,184,549 |
| Cash and Cash Equivalents | $5,227,894 (as of Sept 30, 2024) | ||
| Short-Term Investments | |||
| Total Assets | $7,119,474 | ||
| Working Capital | $6,525,650 | ||
| Net Cash Used in Operating Activities (YTD) | $(2,512,166) |
Material Changes vs. Prior Period
- Revenue Generation: The company recorded nominal revenue of $2,704 in Q3 2024, primarily from health coaching packages, compared to $0 in the same period in 2023.
- Operating Expenses: Total operating expenses decreased by 11.9% year-over-year for the nine-month period ($2.81M vs. $3.18M). This reduction was driven by a significant decrease in stock-based compensation ($84k in 2024 vs. $914k in 2023) and lower impairment losses (none in 2024 vs. $52k in 2023).
- Net Loss Reduction: Net loss for the nine months ended September 30, 2024, decreased by 17.8% compared to the prior year period.
- Liquidity Position: Cash and short-term investments increased significantly from $3.62M at year-end 2023 to $6.64M at September 30, 2024, due to capital raises.
- Capital Structure: The company executed a 1-for-12 reverse stock split effective March 7, 2024. All share data has been retroactively adjusted.
Guidance, Outlook, and Risks
- Capital Raises: In March 2024, the company raised approximately $3.5M gross proceeds via a private placement. In September 2024, it raised an additional ~$3.2M gross proceeds through an inducement offer for warrant exercises.
- Outlook: Management expects to continue generating operating losses in the foreseeable future due to corporate overhead, R&D, and public company costs. They believe current cash and working capital are sufficient for the next 12 months.
- Strategic Initiatives: The company is expanding into "Gaxos Health" and developing a generative AI platform for game developers, with a planned launch in Q4 2024.
- Risks: Key risks include the need for additional financing to sustain operations, the ability to attract users and advertisers, competition in the AI and gaming sectors, and the uncertainty of forward-looking statements regarding profitability.
- Subsequent Events: In October 2024, the company formed a subsidiary, RNK Health, LLC, and entered an operating agreement with Nekwellness, LLC to market GLP-1 and TRT products. Additionally, 978,000 warrant shares held in abeyance as of September 30 were issued subsequent to the period end.
Investor Verification Checklist
- Revenue Sustainability: Verify the source and scalability of the $2,704 revenue recognized, as it is negligible relative to operating costs.
- Cash Burn Rate: Confirm the runway provided by the $6.6M in liquid assets against the current quarterly burn rate of approximately $0.86M.
- Dilution Impact: Review the impact of the 2.67M outstanding warrants and 64k stock options on future share count and per-share value.
- Product Launch Timeline: Monitor the Q4 2024 launch of the AI solution for game developers and the commercial traction of Gaxos Health.
- Related Party Transactions: Scrutinize the October 2024 partnership with Nekwellness and the terms of the RNK Health subsidiary.